Microglia subpopulations were studied in mouse experimental autoimmune encephalomyelitis and toxoplasmic encephalitis. CNS inflammation was associated with the proliferation of CD11b ؉ brain cells that exhibited the dendritic cell (DC) marker CD11c. These cells constituted up to 30% of the total CD11b ؉ brain cell population. In both diseases CD11c ؉ brain cells displayed the surface phenotype of myeloid DC and resided at perivascular and intraparenchymatic inflammatory sites. By lacking prominent phagocytic organelles, CD11c
T he CNS is susceptible to inflammatory diseases, although the healthy organ is immunologically quiescent, presumably due to the blood-brain barrier and the relative lack of intraparenchymatic leukocytes and MHC class II expression. The current concept of brain immunity is based on experimental evidence that activated T cells extravasate into the brain but undergo apoptosis upon contact with local APC or by other microenvironmental signals (1) (2) (3) . An intracerebral T cell response is likely to be further inhibited by the antiproliferative effect of CNS lipids and the constitutive expression of TGF-␤ (4 -7). Despite such limitations imposed on the immune system, vigorous inflammatory responses can rapidly develop within the brain, resulting in the recruitment of naive bystander T cells (8) .
Experimental autoimmune encephalomyelitis (EAE) 3 is a murine model of autoimmune disease directed against CNS Ags. Disease is initiated in animals of susceptible strains by sensitization or the adoptive transfer of neural Ag, e.g., myelin basic protein-specific CD4 ϩ T cells leading to multiple inflammatory, often demyelinating, lesions in spinal cord and brain (reviewed in Ref. 9 ). A prototypic model of infectious CNS inflammation is murine toxoplasmic encephalitis (TE), which is induced by experimental infection with the intracellular parasite Toxoplasma gondii. While TE is transient in mice that are genetically resistant to the pathogen (e.g., BALB/c), susceptible mouse strains (e.g., C57BL/6) develop progressive lethal encephalitis during chronic infection (reviewed in Ref. 10 ). Common to EAE and TE is a type 1 CD4 ϩ T cell-mediated immunopathology, although it is still unclear how the intracerebral T cell response is polarized. In EAE, brain microglia that function as resident APC are thought to skew the cellular response, as they have been shown to preferentially activate Th1 cells (11) . Besides microglia, other potential APC are brain macrophages and astrocytes (reviewed in Refs. 12 and 13) as, of course, are the dendritic cells (DC), which have been recently identified in the brains of BALB/c mice during chronic latent TE (14) . These brain DC seem to be related phenotypically to macrophages/microglia.
Since myeloid DC progenitors are present in the newborn mouse brain (15) and mature upon challenge by T. gondii of glial cells in vitro (14) , the emergence of brain DC in TE raises the question of whether these DC appear and expand as a direct consequence of the presence of the pathogen or as a result of the local inflammatory reaction. In the present study we address the hypothesis that CNS inflammation in general is associated with an intracerebral presence of functional DC. EAE as a noninfectious inflammatory CNS disease and progressive TE as a severe infectious encephalitis were examined for the presence and location of brain DC. Isolated DC were compared with coisolated microglia/brain macrophages with respect to their morphology, T cell stimulatory activity, and cytokine secretion profiles. Furthermore, we delineate a Toxoplasma-independent differentiation pathway that leads from resting microglia to functionally mature DC. Laboratories (Fuellinsdorf, Switzerland) . SJL/NBom mice were obtained from M&B (Ry, Denmark). Mice transgenic for TCR that recognize OVA [323] [324] [325] [326] [327] [328] [329] [330] [331] [332] [333] [334] [335] [336] [337] [338] [339] peptide in the context of I-A d (DO11.10 TCR␣/␤ transgenic mice) on a BALB/c background (16) were provided by Dr. M. Kopf (Basel Institute of Immunology, Basel, Switzerland). EAE was elicited in 8-wkold female SJL mice according to the method of Miller and Karpus (17) by s.c. immunization with 180 g of myelin basic protein 89 -101 peptide (VHFFKNIVTPRTP; synthesized and HPLC purified by the Center for Biological and Medical Research, University of Duesseldorf) in CFA containing 200 g of Mycobacterium tuberculosis H37Ra. In addition, mice were injected i.p. with 400 ng of pertussis toxin (Alexis, Lausen, Switzerland) on days 0 and 2. About 70% of the animals showed symptoms that corresponded to grades 0.5-2 (beginning tail paresis and additional hind limb paresis, respectively) in EAE scoring (17) . Mice were analyzed at the peak of disease. Control animals treated with CFA and pertussis toxin were simultaneously analyzed. Female BALB/c or C57BL/6 mice were infected at 8 -12 wk of age with the DX strain of T. gondii by i.p. injection with three cysts prepared as previously described (14) . Infection was serologically verified 2-3 wk later. Unless otherwise stated, T. gondii-infected mice were analyzed between days 28 and 42 postinfection when TE was histologically apparent.
Bromodeoxyuridine (BrdU) labeling
For pulse-labeling of proliferating cells in vivo, mice were injected i.p. with 1.2 mg of BrdU (Roche, Mannheim, Germany) 12 h before preparation of brain cells.
Immunohistochemistry
Mice were transcardially perfused with ice-cold PBS. The brains were excised, mounted in OCT compound (Sakura, Zoeterwoude, The Netherlands), snap-frozen in 2-methylbutane, and stored at Ϫ70°C. Frozen sections, 5 m thick, were stained with anti-CD11c mAb N418 (Endogen, Cambridge, MA), anti-TCR␤ mAb H57-597 (PharMingen, San Diego, CA), or hamster isotype control mAb G235-2356 (PharMingen) as detailed previously (14) . Ab binding was detected using biotinylated goat antihamster IgG (The Jackson Laboratory, Bar Harbor, ME) and peroxidaseconjugated avidin-biotin complex (Vector Elite ABC kit, Vector, Burlingame, CA). Sections were developed using the 3,3Ј-diaminobenzidine substrate kit (Vector) and were counterstained with hematoxylin.
Preparation of microglia and DC populations
Brains were removed from perfused mice, minced, passed through an 18-gauge needle, and digested by incubation with 250 g/ml collagenase/ dispase and 250 g/ml DNase I (Roche) at 37°C for 45 min each. The resulting cell suspensions were fractionated on 30/60% Percoll gradients at 1000 ϫ g for 25 min (18) , and brain mononuclear cells (BMNC) were collected from the interface. Due to the low number of BMNC obtained, cells from 3-12 mice/experiment were pooled. For isolation of DC or microglial cells, BMNC were depleted of T cells by treatment with antiThy1.2 mAb 30-H12 (PharMingen) and complement (low tox rabbit complement; Cedarlane, Hornby, Canada). Then, CD11c ϩ cells were magnetically sorted by positive selection using N418-coated beads (Miltenyi Biotec, Bergisch-Gladbach, Germany) according to the manufacturer's instruction, resulting in a Ͼ90% pure population as controlled by flow cytometry. Spleen DC were similarly isolated from normal splenocytes. DC-free microglia/brain macrophages were prepared from the residual CD11c Ϫ BMNC by positive selection using M1/70.15-coated magnetic beads (Miltenyi). In general, the resultant population contained Ͼ96% CD11b ϩ and Ͻ0.5% CD11c ϩ cells. For assays, all MACS-enriched cells were resuspended in phenol red-free DMEM with 10% FCS (containing Ͻ10 pg/ml LPS as determined by Limulus amebocyte lysate assay), 2 mM L-glutamine, and 50 M 2-ME.
In vitro differentiation and activation of brain DC
Microglia prepared from normal adult BALB/c mice were plated at 2 ϫ 10 5 cells/ml into low adherence six-well plates (Costar, Cambridge, MA) with medium containing 50 ng/ml murine GM-CSF (provided by Dr. F. Seiler, Behringwerke, Marburg, Germany) and cultivated for 4 -6 days. Microglia were also harvested from GM-CSF-supplemented primary culture of newborn mouse brain (19) . CD11c ϩ cells were then immunomagnetically isolated, washed, and recultured for a further 24 h with GM-CSF. During that time, 10 g/ml soluble CD40L and cross-linking Ab (Alexis) or 10 g/ml LPS (Escherichia coli O55:B5; Difco, Detroit, MI) were added to some cultures to trigger DC terminal maturation.
Flow cytometry
Freshly prepared BMNC or cells isolated from brain cell culture were stained using the following Abs: biotinylated anti-CD11c mAb N418 (Endogen) or HL3 (PharMingen), FITC-labeled anti-F4/80 mAb CI:A3-1 and FITC-labeled anti-DEC-205 mAb NLDC-145 (Dianova, Hamburg, Germany), and PE-or FITC-labeled anti-CD11b mAb M1/70.15, FITC-labeled anti-CD8␣ mAb 53-6.7, and PE-or FITC-labeled anti-CD45 mAb 30-F11 (PharMingen). Species-and isotype-matched control Ab and FITC-or PEconjugated streptavidin as secondary reagent were obtained from PharMingen. To block unspecific binding of primary Ab, cells were preincubated with anti-Fc␥II/IIIR mAb 2.4G2 (PharMingen). Double staining of surface markers was performed according to standard procedures (18) . Propidium iodide was added in the final wash to label dead cells, which were excluded from the analyses. BrdU incorporated into cellular DNA was detected by using the BrdU flow kit (PharMingen). After surface staining, cells were fixed and permeabilized, and DNA was denatured as detailed in the kit protocol. Cells were then incubated with FITC-labeled anti-BrdU mAb 3D4 (PharMingen). All samples were immediately measured on a FACSCalibur flow cytometer, 10 4 events were acquired, and data were analyzed with CellQuest software (Becton Dickinson, Heidelberg, Germany).
Phase contrast and electron microscopy
Freshly isolated CD11c ϩ and CD11c Ϫ microglia/brain macrophages were incubated in culture medium for 6 h at 37°C to allow reconstitution of cell morphology. Light microscopy was performed on a Zeiss photomicroscope III (Zeiss, Jena, Germany). For standard electron microscopy, cells were fixed in Karnovsky's solution, postfixed in 2% osmium tetroxide, dehydrated in ethanol, and embedded in Durcupan ACM (Fluka, Neu-Ulm, Germany). Ultrathin sections were stained with uranyl acetate and lead citrate, and examined using a Zeiss EM 109 transmission electron microscope.
Mixed leukocyte reaction

CD11c
ϩ splenocytes and BMNC, CD11c Ϫ /CD11b ϩ BMNC, or in vitro differentiated brain DC were tested as stimulators of allogeneic T cell responses by MLR. T cells were prepared from spleens of C57BL/6 mice by passing splenocytes through nylon wool and an Ab-coated T cell enrichment (R&D Systems, Minneapolis, MN) column. In A/2 microtiter wells containing 100 l of IMDM with 5% FCS, glutamine, and antibiotics, 1.5 ϫ 10 5 purified T cells (Ͼ99% CD3 ϩ ) were mixed with titrated numbers of gamma-irradiated APC of BALB/c origin. On day 3 test cultures were fed by adding 50 l of medium. T cell proliferation was measured via 
Priming and activation of TCR transgenic T cells
To analyze T cell priming by brain APC, naive T cells purified from DO11.10 mice were exposed in primary stimulation culture to sorted CD11c ϩ or CD11c Ϫ /CD11b ϩ BMNC from chronically T. gondii-infected BALB/c mice. CD11c ϩ normal splenocytes that had been immunomagnetically depleted of CD45R ϩ cells by negative selection using B220-coated microbeads (Miltenyi) served as reference APC. Naive T cells were purified from the spleens of 8-wk-old DO11.10 mice via nylon wool and a T cell enrichment column and subsequent sorting for CD62L high cells using MEL14-coated magnetic beads (Miltenyi). In a total volume of 1 ml (48-well plate), 5 ϫ 10 5 DO11.10 T cells were coincubated with 5 ϫ 10 4 irradiated APC as described above, but in medium containing 0.3 or 1 M OVA 323-339 peptide (ISQAVHAAHAEINEAGR; synthesized and HPLC purified by the Center for Biological and Medical Research, Duesseldorf, Germany). On day 3 cultures were fed with 1 ng/ml IL-2. Subsequently, proliferating T cells were allowed to expand by transfer to 24-well plates.
On day 6 T cell blasts were washed, and 2 ϫ 10 5 cells/200 l were plated using medium without IL-2 in microtiter wells precoated with anti-CD3⑀ mAb (1 g/ml). Supernatants (SN) from restimulated T cells were collected at 24 h and were stored at Ϫ70°C until tested for cytokine content. (IFN-␥) pg/ml, respectively. In 3-day SN from brain cell cultures, the concentration of nitrite indicating cellular NO production was determined photometrically with the Griess reagent and an NaNO 2 standard (20). The detection limit of this assay was 2.5 nM NO 2 Ϫ .
Cytokine assays and measurement of NO production
Statistics
The significance of differences was examined by Student t test, using Prism software (GraphPad, San Diego, CA), and p Ͻ 0.05 was considered significant.
Results
In CNS inflammation the number of microglial cells/brain macrophages increases, consistent with proliferation of CD11b
ϩ and CD11c ϩ brain cells
Microgliosis is a sign of CNS inflammation (21) . For a quantitative approach mononuclear cells were prepared from perfused normal and inflamed brain, and the percentage of CD11b ϩ cells was determined by flow cytometry. As calculated from the BMNC number in pooled cell isolates, on the average, 3 ϫ 10 5 CD11b ϩ mononuclear cells were recovered per brain of normal adult mice (Table  I) . In EAE and TE as experimental models of brain inflammation, the total yield of BMNC increased, which is partially due to T cells infiltrating the CNS (data not shown). In parallel, the number of CD11b ϩ cells increased, correlating with the severity of disease (Table I) . Although the origin of the expanding cells remains unclear, evidence that a proliferation of CD11b ϩ cells contributes to this increase was obtained by pulse-labeling in vivo with the thymidine analogue BrdU; while mononuclear cells from control brains showed no substantial DNA synthesis, those from encephalitic brains contained approximately 10% BrdU-labeled cells, which, by double staining, were identified as microglia and T cells. About 3% of all CD11b ϩ BMNC had incorporated the BrdU label (Fig. 1A) . In comparison, the proportion of BrdU-positive cells among CD3 ϩ brain cells was 6 -7% (Fig. 1B) . The detection of cycling microglia in EAE and TE confirms a previous observation in graft-vs-host disease (22) . Collectively, these results indicate a proliferative reaction in a subset of microglia/macrophages from encephalitic brains.
As recently shown, DC emerge in the brains of BALB/c mice early in chronic latent toxoplasmosis (14) . To test whether these cells proliferate, BMNC were stained for intracellular BrdU and surface CD11c. Flow cytometric analysis revealed that DC in the inflamed brain were cycling, as has been observed for microglia (Fig. 1C) . Within the BrdU-positive gate approximately 60% of brain cells expressed the pan-DC surface marker CD11c (Fig. 1D) . These data identify DC as a major population within the proliferating BMNC population during the onset of CNS inflammation.
In EAE and TE, CD11b ϩ BMNC that coexpress CD11c appear at inflammatory sites and exhibit a comparable DC phenotype
To test whether CNS inflammation is generally associated with local expansion of DC, BMNC from autoimmune and severe infectious encephalitis were analyzed for the presence of DC. In brain cells from SJL mice during EAE as well as in those from C57BL/6 mice during progressive lethal TE, DC were identified within the CD11b ϩ cell pool ( Fig. 2A) . While only minute numbers were detected among CD11b ϩ mononuclear cells from normal brain, CD11b ϩ cells from encephalitic brain contained significant numbers (up to 30%) of cells that proved similar to myeloidrelated DC. Double stainings showed that CD11c ϩ brain cells in EAE lacked CD8␣ and DEC-205, but coexpressed CD11b and F4/80 (Fig. 2B) . By phenotype, the CD11c ϩ BMNC in EAE thus correspond to those in TE (14) and further resemble normal mouse bone marrow-derived DC (23). In agreement with previous studies (24 -26), CD45 was expressed at a low level on mononuclear cells from normal brain. By contrast, CD45 was markedly up-regulated on encephalitic BMNC (Fig. 2C) . In an attempt to define levels of surface CD45 expression in CD11b ϩ brain cell populations, BMNC from inflamed brain (progressive TE, wk 6 postinfection) were depleted of T cells and immunomagnetically sorted for CD11c ϩ vs CD11c Ϫ /CD11b ϩ cells. Fig. 2D shows that the purified brain DC expressed CD45 at high and intermediate levels, while all CD11c
Ϫ microglia/brain macrophages exhibited a CD45 high phenotype. In EAE, brain DC colocalized at inflammatory foci with T cells, as detected by immunohistochemical staining of CD11c and TCR (Fig. 3A-C) . Brain DC were found at perivascular and intraparenchymatic sites of inflammation. A comparable pattern in tissue distribution of brain DC was observed in progressive ( Fig. 3D ) and chronic latent TE (14) . In immunized SJL mice, CD11c ϩ brain cells were detected only when EAE was apparent. Local expansion of DC possibly starts with few cells dispersed in parenchymatic areas lacking substantial leukocyte infiltrates (Fig. 3E) . In TE, a correlation between the number of brain DC and the severity of disease was evident. By comparison, significantly more brain DC were isolated in progressive than in chronic latent disease (Table  I ). In BMNC from T. gondii-resistant BALB/c mice after recovery from TE and in BMNC from immunized, but asymptomatic, or mock-immunized SJL mice, few DC could be identified only by flow cytometry. (Fig. 4, A and B) . Thereby, CD11c ϩ brain cells closely resemble bone marrow-derived DC (23) . As a rule, the brain DC population contained some 
mitotic cells. Coisolated CD11c
Ϫ /CD11b ϩ BMNC became adherent, with extending pseudopodia and branched cytoplasmic protrusions. Ultrastructural characteristics included phagosomes, prominent vacuoles and mitochondria, and abundant rough endoplasmatic reticulum (Fig. 4, C and D) . Comparative measurement of cytokine secretion ex vivo (Fig. 5) identified encephalitic brain DC to release predominantly IL-12p70. CD11c
Ϫ inflammatory microglia/brain macrophages, by contrast, proved superior in secretion of TNF-␣ and GM-CSF and production of NO ( p Ͻ 0.005). IL-1␣ and IL-10 were released by both cell populations; the higher levels at CD11c Ϫ microglia/macrophages were not significant ( p Ͼ 0.05). These results characterize brain DC as inflammatory cells specialized in IL-12 secretion, whereas CD11c Ϫ /CD11b ϩ BMNC, by producing TNF-␣ and NO, resemble inflammatory macrophages.
DC and CD11c Ϫ microglia/macrophages from inflamed brain qualify distinct in induction of T cell proliferation, but similarly prime naive T cells for a Th1 response
To assess CD11c ϩ brain DC and CD11c Ϫ /CD11b ϩ BMNC for their capacities to stimulate an alloreactive T cell response, cells coisolated from encephalitic brain were used in MLR. Titrated numbers of both APC types were cocultured, each with a fixed number of allogeneic T cells. Fig. 6A shows that DC derived from inflamed brain were potent stimulators, already inducing T cell proliferation at a ratio of 1 cell per 100 T cells. CD11c Ϫ /CD11b ϩ inflammatory BMNC proved about 4-fold less efficient. Similarly, CD11c ϩ cells from normal adult BMNC were significantly superior in T cell stimulation ( p Ͻ 0.05) compared with residual CD11c Ϫ /CD11b ϩ brain cells (Fig. 6B) , thus indicating that potent stimulator cells were enriched. The level of T cell response induced by brain DC was comparable to that induced by spleen DC as reference stimulator cells and is consistent with previous studies that suggest that brain microglia comprise cells active in allo-MLR (26, 27) .
During CNS inflammation, brain APC can encounter naive T cells that extravasate into the parenchyma (8) . To address the question of how naive T cells are primed by brain DC and other microglia/brain macrophages, cells isolated from BALB/c mice suffering from TE were used to stimulate CD4 ϩ /CD62L high T cells from OVA TCR transgenic mice in the presence of OVA 323-339 peptide. T cell activation was strictly dependent on the presence of peptide. T cell expansion during the 6-day primary stimulation culture confirmed the superior capacity of brain DC to trigger naive T cell proliferation (data not shown). The cytokine secretion pattern of OVA TCR transgenic T cells primed with brain DC or CD11c Ϫ microglia/brain macrophages was determined after secondary stimulation with anti-CD3⑀. T cells primed with brain DC as well as those primed with CD11c
ϩ BMNC secreted high levels of IFN-␥ and IL-2, minimal amounts of IL-4, and no IL-10 ( Fig. 7) . Taking into account that brain DC are superior in stimulating naive T cell proliferation, they can be considered the principal inducers of Th1 responses in inflamed CNS tissue.
Functional DC differentiate from resting microglia due to exposure to GM-CSF and CD40 ligation
Since microglia from adult mouse brain or brain cell primary culture share functional and phenotypic characteristics with immature DC (15, 26) , we tested whether mature DC can differentiate from microglia. Resting microglia were prepared from adult mouse brain and depleted of CD11c ϩ cells, resulting in 96 -99% F4/80 ϩ / CD45 low cells as controlled by flow cytometry (Fig. 8A) . To stimulate differentiation to DC, isolated microglia were maintained with GM-CSF for 6 days. While a subpopulation of cells rapidly adhered by exhibiting a ramified morphology, a further population of veiled or dendriform cells remained in suspension, often forming clusters (Fig. 8, B and C) . At the concentration used to promote differentiation of brain DC, GM-CSF did not induce cellular proliferation, as assessed by [ 3 H]TdR incorporation (not shown). After 5 days of incubation with GM-CSF, approximately 30% of cells expressed CD11c (Fig. 8D ) compared with Ͻ0.5% of cells in the initial population. Testing by MLR of sorted CD11c ϩ cells revealed their allostimulatory capacity, although these microgliaborn APC were significantly less potent than reference splenic DC. Engagement of CD40 by overnight incubation with a CD40 agonist, however, resulted in full competence to trigger maximum proliferation of alloreactive T cells (Fig. 8E) . Similar results were obtained when using microglia derived from primary brain cell culture, although their basic stimulatory capacity was minimal compared with that of ex vivo microglia (Fig. 8F) . Measurement of IL-12 secretion confirmed the activation of CD11c ϩ microglia via CD40 ligation (Fig. 8G ). These findings demonstrate a GM-CSF-dependent differentiation of microglia to DC and their functional maturation in response to CD40 signaling.
FIGURE 5. Production of cytokines and NO by DC and CD11c
Ϫ microglia/macrophages from encephalitic brain. BMNC were prepared from T. gondii-infected C57BL/6 mice at peak encephalitis (at wk 5 postinfection) and cells pooled from five to eight animals were immunomagnetically sorted for CD11c ϩ and CD11c Ϫ /CD11b ϩ cells. Secretion of IL-12p70, TNF-␣, GM-CSF, IL-10, and IL-1␣ was tested by ELISA on aliquots of both populations incubated for 24 h ex vivo. NO production was determined via the release of nitrite during 72 h of incubation. Values are the mean Ϯ SD from triplicate SN productions. Profiles shown are representative of at least three experiments. ϩ normal spleen cells as primary stimulators, the IL-4 response amounted to 3.7 Ϯ 0.14 ng/ml, while no IL-10 was detectable. This experiment was repeated five times, producing similar cytokine secretion patterns.
Brain DC functionally mature during prolonged encephalitis
Based on our observation that resting microglia can acquire a DC phenotype and develop into functionally mature DC, we tested whether brain DC isolated during all stages of transient CNS inflammation vary in their maturational stage. Since CD11c is expressed on both immature and mature DC, sorting of CD11c ϩ cells as a final step in the isolation procedure yields highly enriched DC regardless of their individual maturational stage. The relative proportions of fully matured DC among CD11c ϩ BMNC isolated at different time points during transient TE were estimated by their allostimulatory capacities in MLR. Compared with cells from normal brains, DC prepared from the brains of BALB/c mice at the onset of TE (day 14 postinfection) showed a significantly ( p Ͻ 0.005) elevated capacity to stimulate alloreactive T cell proliferation (Fig. 9) . Maximum levels in T cell stimulation were measured on brain DC prepared during ongoing CNS inflammation (day 24 or 36 postinfection) or later when encephalitis in those mice resistant to infection with T. gondii was resolved (day 77 postinfection). These results indicate that a maturation of brain DC occurs in periods of apparent CNS inflammation and that functionally mature DC continue to be present in the brain after termination of a local inflammatory process.
Discussion
The mechanisms underlying the initiation and control of T cell responses in CNS inflammation are poorly understood. Resident brain cells, e.g., microglia (28) , are undoubtedly involved as APC in the stimulation or reactivation of CNS-targeted T cells. However, it is unclear which cells initiate and amplify such responses before IFN-␥ is produced and prime naive T cells entering the inflamed brain. The present data demonstrate in autoimmune and infectious encephalitis that CNS inflammation is associated with the local emergence of DC that perform these functions. Concomitant to microglia proliferation at disease onset, myeloid-related DC appear and expand at inflammatory sites within CNS tissue and functionally mature as disease progresses. Generation of DC from microglia, as proved ex vivo, may represent a brain-intrinsic mechanism by which the organ acquires full immunoreactivity upon inflammatory challenge and which may favor the chronicity of cellular responses in the CNS.
To date, DC have not been identified in the normal adult brain, whereas outside the blood-brain and meningeal barriers MHC class II ϩ dendriform cells have been localized in the dura mater, leptomeninges, and choroid plexus (29, 30 ). An intraparenchymatic presence of DC was indicated by the detection of cells exhibiting MHC class II or DC markers in delayed-type hypersensitivity and EAE lesions (31) (32) (33) and was evidenced on cell isolates in TE (14) . Consistently, an intracerebral expression of the DC-specific MHC class II transactivator has recently been observed in mouse EAE (33) . By immunohistochemistry in combination with ex vivo phenotyping and testing of brain cells for DC functions, we show here that activated myeloid DC accumulate at perivascular cuffs and parenchymatic foci in the brains of mice suffering from EAE or TE.
It is possible that blood-borne or meningeal DC are recruited by extravasation and via the perivascular space, respectively, to inflammatory sites within the CNS parenchyma. Alternatively, DC can differentiate from monocytes (34) that infiltrate the inflamed brain. Several lines of evidence support a third possibility, a GM-CSF-driven differentiation of brain DC from local, probably microglial, progenitors. It has been shown that the adult brain parenchyma harbors CD11b ϩ myeloid precursors (35) , and immature DC develop in primary culture with GM-CSF (15, 19) . GM-CSF, which promotes the development of DC from bone marrow progenitors (23) , is produced by glial cells upon exposure to inflammatory or microbial stimuli (36 -38) . Consistently, in EAE and TE, expression of GM-CSF is induced early during the onset of disease (39, 40) . Intracerebral expression of CSF-1, as a cofactor required by immature brain DC for preserving GM-CSF-dependent APC function (15) , is likewise up-regulated early in EAE (41) . Furthermore, GM-CSF-triggered development of myeloid DC is accompanied by cellular proliferation (23) , which agrees with the findings that most cycling cells from encephalitic brain were CD11c ϩ and that mitotic cells were enriched in CD11c ϩ , but not in CD11c Ϫ /CD11b ϩ , brain cell isolates. Finally, the progressive functional maturation of brain DC after the onset of encephalitis is compatible with a local development of DC. In contrast, an already advanced maturational stage, as would be expected for immigrating DC by virtue of their motility (42) , would conflict with the early proliferative activity observed. Accordingly, in EAE single CD11c ϩ parenchymatic cells were sometimes seen at a distance from T cell infiltrates, which renders a common influx of T cells and DC unlikely.
Evidence for a microglia differentiation pathway leading to brain DC is provided by the generation of potent allostimulatory CD11c ϩ cells from normal resting microglia ex vivo. This development was independent of IFN-␥. The alteration of function and surface phenotype was detected on microglia regardless of whether they originated from normal adult brain or primary culture, thus excluding the possibility that the enzymatic extraction of brain cells might have influenced their functional potential. GM-CSFinduced expression of the pan-DC marker CD11c was accompanied by the acquisition of DC-like morphology and T cell-stimulatory activity; therefore, the cells were designated DC. In recent studies the GM-CSF-dependent differentiation step has been designated microglia activation or functional maturation. Exposure of a microglia cell line or adult microglia to GM-CSF induced upregulation of CD80/B7.1 and MHC class II surface expression and of Ag-directed Th1 stimulatory capacity, respectively (25, 43) . However, whether such GM-CSF-treated microglial cells exhibited DC markers was not analyzed in these studies. A model integrating the putative differentiation pathway(s) of brain DC and their relationship to the microglia/macrophage lineage is shown in Fig. 10 . Upon trigger by GM-CSF, e.g., from reactive astroglia, microglial cells can differentiate via two steps into functional DC that finally die by apoptosis. Such a concept obtains support from the even tissue distribution of MHC class II ϩ dendritic-like cells in rat EAE in the prefinal state (32) and the early emergence of CD11c ϩ parenchymatic cells (Fig. 3E ) and allows the migration of brain DC from intraparenchymatic sites also.
Despite the disparate etiology of both CNS disorders, brain DC in EAE and TE exhibit a similar CD11c 
CD11b
ϩ BMNC isolate from progressive TE might be due to the relative rarity of microglial cells among the exogenous-derived inflammatory macrophages and the preceding separation of CD11c ϩ cells, which, indeed, contained considerable numbers of cells expressing CD45 at a low to intermediate level. Another explanation would be an up-regulation of CD45 on resident microglia under the conditions of progressive lethal TE. No correlation between the level of CD45 expression and the expression of CD11c was found on encephalitic BMNC.
With regard to cell morphology and ultrastructure, the brain DC strikingly resembled bone marrow (23) or liver-derived DC (44) , whereas most inflammatory CD11c
Ϫ microglia/brain macrophages exhibited features of other tissue macrophages. Distinctive immune functions were the secretion of IL-12p70 and efficient induction of proliferative T cell responses by brain DC, and the production of TNF-␣, GM-CSF, and NO by CD11c Ϫ /CD11b ϩ BMNC, respectively. Based on these profiles, non-DC CD11b ϩ brain cells seem to be predestined as amplifier and effector cells of CNS inflammation. Among them, microglia and brain macrophages can alternate in TNF-␣ production (45) . By producing IL-10, inflammatory microglia/brain macrophages might provide a local counter-regulation of IL-12 effects (46 -48) . While in TE, NO is crucial for parasite inhibition (49) , the role NO plays in CNS autoimmunity, mediating tissue damage or antagonizing autoaggressive cellular activity, is still debated (50) .
On the other hand, brain DC functionally resemble (by their weak IL-10 production and strong Th1-inducing capacity) bone marrow-derived and splenic DC, but not liver-derived or Peyer's patch DC (51, 52) , and thus must be considered initiators of Th1-mediated CNS immunopathology. The Th1-promoting activity of brain DC and their long-lasting presence even after resolution of a local inflammatory process suggest a key role in the exacerbation or maintenance of immune-mediated CNS diseases. As stimulators of naive T cells infiltrating the inflamed brain, these DC might be crucially involved in the phenomenon of epitope spreading during chronic T cell-mediated autoaggression against CNS Ags. Whether microglia are primed in situ to differentiation into the Th1-inducing DC type by IFN-␥, as has been demonstrated on human monocyte-derived DC (53), or by another, possibly tissue-specific, mechanism remains an issue relevant for future brain DC-targeted immune intervention.
